Teva to present data on central nervous system portfolio

Teva is to present the results of a number of clinical studies on treatments for central nervous systems conditions at a forthcoming medical conference.

The generic pharmaceuticals specialist will attend the American Academy of Neurology Annual Meeting later this month to detail the developmental progress of therapies for multiple sclerosis (MS) and Parkinson’s disease.

Among the data to be presented is analysis of a placebo-controlled trial of the Parkinson’s drug Azilect, designed to highlight the effects of the illness and the treatment’s efficacy in severe cases.

MS treatment Copaxone will also be spotlighted with data showing its effect on the immune system and benefit-risk profile.

Further presentations will also be given on developmental MS drug laquinimod and acute optic neuritis therapy glatiramer acetate.

Last month, Teva agreed to purchase the German generic drug company Ratiopharm, a merger which will create Europe’s largest generics specialist.